Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2 https://doi.org/10.1111/cts.12894 This was a multi-center study with data collected by chart review both retrospectively and concurrently. 145 patients were evaluated. The average age was 58.1 years, 64% were… Continue reading "(12 Sep 2020) Tocilizumab- early dosing associated with increased survival"
COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY https://www.medrxiv.org/content/10.1101/2020.09.07.20189357v2.full.pdf During the study period, 506 patients with severe COVID-19 fulfilled inclusion criteria. Among them, 268 were treated with tocilizumab and… Continue reading "(10 Sep 2020) Tocilizumab- combined with steroids increases survival rate"
Tocilizumab for severe COVID-19 related illness – A community academic medical center experience https://doi.org/10.1016/j.cytox.2020.100035 In an academic community medical center,31 patients with anti-IL-6/IL-6-R agents including 12 who had already been intubated were treated with TCZ. Overall, 27 (87%) patients are… Continue reading "(08 Sep 2020) Tocilizumab- effective in managing early CRS related to COVID-19 disease"
The impact of the “low molecular weight heparin” administration on the clinical course of COVID-19 disease https://doi.org/10.3906/sag-2006-184 This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19. Participants… Continue reading "(07 Sep 2020) LMW Heparin- D-dimer, and CRP levels were significantly improved in the LMWH group"
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial https://doi.org/10.1016/S0140-6736(20)31862-6 An open-label, randomised clinical trial (NCT04321278) at… Continue reading "(07 Sep 2020) Azithromycin- No benefit seen with routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19"
Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study https://doi.org/10.1007/s40121-020-00332-3 A retrospective study based on propensity score matching was designed to explore the effects of corticosteroids. Primary outcomes included the rate… Continue reading "(04 Sep 2020) Corticosteroids-early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes"
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial https://doi.org/10.1001/jama.2020.17021 A multicenter, randomized, open-label, clinical trial (NCT04327401) was conducted in 41 intensive care units… Continue reading "(03 Sep 2020) Dexamethasone- statistically significant increase in the number of ventilator-free days"
Dual-Histamine Receptor Blockade with Cetirizine – Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients https://doi.org/10.1016/j.pupt.2020.101942 A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a… Continue reading "(02 Sep 2020) Famotidine- in combination with cetrizine exhibited beneficial reductions in inpatient mortality and symptom progression"
Hydroxychloroquine for preexposure prophylaxis for SARS-CoV-2 https://doi.org/10.1101/2020.08.31.20185314 This is a retrospective cohort study. The exposed cohort was formed by individuals with autoimmune diseases with HCQ treatment. The control cohort was randomly selected using the Health Card database. To deal with… Continue reading "(02 Sep 2020) Hydroxychloroquine- did not offer preexposure prophylaxis"
Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness https://doi.org/10.1101/2020.08.31.20182428 A total of 1,092 COVID-19 patients were admitted during the study period. Of them, 186 (17%) were treated with TCZ, of which 129… Continue reading "(01 Sep 2020) Corticosteroids and Tocilizumab- combination therapy protective against in-hospital mortality"
